Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...

We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

These two could become direct competitors relatively soon.

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Sarepta dominates the Duchenne muscular dystrophy market. Find out why recent insider buying of SRPT stock may signal ...

Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...